MU
Michael Ulz Morgan Stanley Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
28
Avg Return
Past Year
Past Year
34%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past 3 Months
Positive
50%
Neutral
50%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 3 Months |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Maintained
| $47 |
209%
upside
| 2 | -17% |
0
%
| 3 Mar ‘26 2 days ago |
|
|
|
Equal-Weight
Downgraded
| $7 |
22%
upside
| 1 | +23% |
0
%
| 2 Mar ‘26 3 days ago |
|
|
|
Equal-Weight
Downgraded
| $2 |
301%
upside
| 1 | -68% |
–
| 30 Jan ‘26 1 month ago |
|
|
|
Overweight
Maintained
| $123 |
40%
upside
| 2 | +8.7% |
0
%
| 30 Jan ‘26 1 month ago |
|
|
|
Equal-Weight
Maintained
| $408 |
27%
upside
| 1 | – |
–
| 30 Jan ‘26 1 month ago |
|
|
|
Equal-Weight
Maintained
| $81 |
27%
upside
| 1 | – |
–
| 7 Jan ‘26 1 month ago |
|